Cardiac amyloidosis prevalence and 1-year outcome in patients with aortic stenosis undergoing transaortic valve implantation: Findings from the CAMPOS-TAVI study - 25/09/24
, Ahmed El-Ali a, David Morland b, c, d, Sebastien Dejust b, Dimitri Papathanassiou b, c, d, Pierre Nazeyrollas a, e, Damien Metz a
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Graphical abstract |
Highlights |
• | One in 14 patients (7%) with severe AS undergoing TAVI diagnosed with ATTR-CM. |
• | Targeted screening with Tc99m BS in those at risk (red flags and/or risk scores). |
• | Monoclonal gammopathy excluded. |
• | Emphasis on tailored management for patients with positive BS. |
• | Management includes consideration of TTR stabilizers. |
• | Continued surveillance for ATTR-CM in high-risk patients with negative BS. |
• | More studies needed to define impact of ATTR-CM on long-term prognosis after TAVI. |
Abstract |
Background |
Transthyretin amyloid cardiomyopathy (ATTR-CM) can manifest as rhythm disorders, heart failure, but also valvular degeneration. Despite aortic stenosis (AS) being prevalent among the elderly, data on ATTR-CM prevalence and outcome in patients with AS undergoing transaortic valve implantation (TAVI) remain scarce.
Aim |
To determine ATTR-CM prevalence and evaluate 1-year survival in patients undergoing TAVI.
Methods |
Between December 2020 and September 2021, 100 consecutive patients underwent TAVI and were screened prospectively for ATTR-CM using bone scintigraphy (BS). Monoclonal gammopathy was ruled out in case of cardiac uptake on BS. All patients were followed prospectively for 1year after TAVI.
Results |
The proportion of patients aged≥75years or with a EuroSCORE II>8% and possible femoral access was 99%. The abnormal cardiac uptake rate on BS was 7% (95% confidence interval: 2–12%); 86% of these patients were male. The RAISE (remodelling, age, injury, system and electrical) score, indicative of ATTR-CM risk, was higher in case of positive BS (P=0.04). Patients with positive BS were older and exhibited wider QRS complexes on electrocardiography (P=0.003), a higher frequency of reduced LVEF (57% vs. 17%), impaired basal LV strain (P=0.02) and a lower voltage/mass ratio (P=0.01). History of pacemaker implantation before TAVI was higher in the positive BS group (P=0.0004) and remained the only statistically significant factor after adjustment using the Holm–Bonferroni method. One-year survival of patients with positive BS did not differ from that of patients with isolated AS.
Conclusions |
Prevalence of ATTR-CM in patients treated with TAVI, underscoring the need for continued surveillance for potential development of ATTR-CM after TAVI. Caution is warranted regarding the 1-year survival because of the lack of study power. Further investigations are needed to define long-term prognosis of AS with ATTR-CM.
El texto completo de este artículo está disponible en PDF.Keywords : Amyloid transthyretin cardiomyopathy, Severe aortic stenosis, Transaortic valve implantation, Bone scintigraphy, Heart failure
Esquema
| ☆ | Tweet: Exploring transthyretin cardiac amyloidosis (ATTR-CM) in TAVI patients with low to high risk (CAMPOS-TAVI): Study finds 7% prevalence using bone scintigraphy. No difference in 1-year mortality rates; importance of targeted screening and surveillance for timely ATTR-CM detection and management. #Amyloidosis #AorticStenosis #TAVI #HeartFailure. |
Vol 117 - N° 8-9
P. 461-469 - août 2024 Regresar al número
Artículo precedente
- Is coronary artery disease screening by imaging in patients with chronic kidney disease necessary?
- Benoit Caullery, Gilles Barone-Rochette
- Cardiogenic shock and infection: A lethal combination
- Miloud Cherbi, Hamid Merdji, Vincent Labbé, Eric Bonnefoy, Nicolas Lamblin, François Roubille, Bruno Levy, Pascal Lim, Hadi Khachab, Guillaume Schurtz, Brahim Harbaoui, Gerald Vanzetto, Nicolas Combaret, Benjamin Marchandot, Benoit Lattuca, Caroline Biendel-Picquet, Guillaume Leurent, Edouard Gerbaud, Etienne Puymirat, Laurent Bonello, Clément Delmas
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.